Terns Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Terns Pharmaceuticals

08/08/2023 23:33

* Terns Pharmaceuticals Inc  TERN.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
June. The mean expectation of nine analysts for the quarter was
for a loss of 34 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Terns Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 25 cents​.
    * The mean earnings estimate of analysts had fallen by
about 24.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Terns Pharmaceuticals Inc shares had fallen by 23.9% this
quarter and lost 34.6% so far this year.
    * The company reported a quarterly loss of $17.9 million.
    * Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:33 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.34          -0.25          Beat
 Mar. 31 2023      -0.27          -0.31          Missed
 Dec. 31 2022      -0.43          -0.29          Beat
 Sep. 30 2022      -0.52          -0.44          Beat